Provider file · rigor-forward model · on-record
Enhance MD: the file as of August 17, 2026
Latest first-party read (September 17, 2026), from the open dataset. Enhance.MD (read September 17, 2026 at enhance.md): tirzepatide — $280/mo: $280 12-month plan, nothing billed beside it — term paid up front; flags: term prepaid, billed every 4 weeks; dose policy same price at every dose; labs not advertised; pharmacies none named; cancellation: full refund of the initial payment if found ineligible. The file below records this site’s earlier, dated read; any figure it carries that the provider’s page no longer prints is kept as dated history and is not ranked. Dated pages, regenerated on every build: compounded tirzepatide online price · compounded semaglutide online price · NexLife true monthly cost · news ledger.
Enhance MD sells a rigor-forward architecture: mandatory baseline metabolic labs (CMP, lipids, TSH, HbA1c at a national lab chain) and a synchronous video visit with a board-certified clinician before any prescription — a heavier onboarding than the async norm — across three tiers (semaglutide, tirzepatide, combined). The pricing shape demands the annualization reflex: intro offers from ~$112–$169 first month; ongoing rates $212–$322/month on twelve-month plans or $249–$379 month-to-month. Captured 2026-08-17.
How to read it
The labs-and-video layer is a real service — it is, in effect, the lab panel and a slice of the oversight file bundled into intake — and the honest comparison prices it against assembling the same stack à la carte (an audited $139 plan plus a covered E&M visit plus direct-pay labs often totals less). The intro-versus-ongoing gap is the file’s caution: judge the $212–$322, never the door.
Open files
Dose-scaling behavior within tiers · pharmacy identity · exit terms · independent walk.
Standing rules apply: compounded products are not FDA-approved; trial certificates belong to the brands; tier upgrades require the same audit the anchor passed, and corrections@ outranks this page with dated evidence. Field context: the cost index · tirzepatide value board · semaglutide value board.
Outbound link withheld pending direct capture of pricing pages (figures via independent comparison coverage, 2026-08-17).